Brief: First Patient Enrolled In 60 Degrees Pharmaceuticals Clinical Trial Of Tafenoquine For Babesiosis At Tufts Medical Center First And Only Study Of Its Kind
27/06/2024 13:36
June 27 (Reuters) - 60 Degrees Pharmaceuticals Inc
SXTP.O :
* FIRST PATIENT ENROLLED IN 60 DEGREES PHARMACEUTICALS
CLINICAL
TRIAL OF TAFENOQUINE FOR BABESIOSIS AT TUFTS MEDICAL CENTER;
FIRST AND ONLY STUDY OF ITS KIND
Source text for Eikon: ID:nGNX96hcZ4
Further company coverage: SXTP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on 60 Degrees Pharmaceuticals
See all newsBrief: 60 Degrees Pharmaceuticals Says May Submit NDA For Tafenoquine To FDA Before End Of Q1 2028 - SEC Filing
U.S. RESEARCH ROUNDUP-Analog Devices, Intuit, NVIDIA
Brief: 60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (Ndin) With FDA For Australian Chestnut Extract
NASDAQ RESUMED AT 10:06 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:55 AM